Randomised clinical trial: a placebo-controlled study of subcutaneous or intradermal NEXVAX2, an investigational immunomodulatory peptide therapy for coeliac disease.

Kenneth E TruittA James M DavesonHooi C EeGautam GoelJames MacDougallKristin NeffRobert P Anderson

Published in: Alimentary pharmacology & therapeutics (2019)

Subcutaneous and intradermal dosing of Nexvax2 yield similar bioavailability of constituent peptides; subcutaneous dose escalation avoids an immune response to dominant gluten epitopes.

Keyphrases

clinical trial
open label
double blind
phase ii
study protocol
placebo controlled
randomized controlled trial
phase iii
celiac disease